Reviews/Osteoporosis Fracture Prevention/Anabolic-first sequential therapy bone mineral density
Anabolic And Sequential Therapy · ostfrac_11 · v2
The question is whether starting osteoporosis treatment with a bone-building (anabolic) drug and then following with a resorption-blocking drug builds more bone density than the reverse or than blockers alone. One direct comparison [1] found the anabolic-led sequence produced clearly larger density gains at spine, hip and femoral neck. Other studies in the set agree in direction: density gains from an anabolic start are held and extended when a blocker follows [4], and can be pushed higher by adding a blocker during the anabolic phase [6]. But that one direct comparison was a statistical re-analysis of trial cohorts treated at different times, not a trial that randomly assigned people to one sequence or the other, and no study here ran the two orders head-to-head. The panel judged the claim well supported in direction but short of settled because the single direct test is observational and thin.
The corpus contains one direct test of the sequence claim [1], a post hoc propensity-weighted comparison of romosozumab-then-denosumab versus denosumab-only, showing significantly greater BMD gains at lumbar spine, total hip and femoral neck (mean differences 9.3%, 4.4%, 4.1%, all p<0.001). Supporting evidence shows an anabolic-first gain is maintained at spine and raised at hip when an antiresorptive follows [4], and that adding alendronate during ongoing teriparatide gives additional spine and hip BMD [6]. In a post-bisphosphonate setting the dual-action agent romosozumab produced the largest BMD gains (LS 11.4% vs 6.3% and 5.9%) [2]. Direction is consistent across the included primary studies, with the claim's endpoint (BMD) measured directly. The contested point: The division is over strength of design, not direction: the only head-to-head superiority result [1] is an observational re-analysis of non-concurrent cohorts, not a randomised sequence trial. The remaining primary studies either lack a reverse-sequence arm [4] or test combination rather than sequential therapy [6], so no eligible study randomises anabolic-first against antiresorptive-first.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole direct superiority finding ([1]) is a post hoc, propensity-weighted comparison of non-concurrent cohorts (months 0-24 vs 12-36), not a randomised head-to-head of treatment sequence; residual confounding remains possible despite E-value adjustment.
No included primary paper is a randomised anabolic-first vs antiresorptive-first sequence trial for BMD: [4] has no reverse-sequence arm and [6] is combination therapy, not sequential, so the comparative claim is under-supported by eligible primary data.
Where it remains uncertain. The single direct superiority test [1] is a post hoc analysis of non-concurrent cohorts, and no included primary study randomises anabolic-first against antiresorptive-first [4][6].
Aleatory
BMD superiority is clearest at the spine and smaller at the hip and femoral neck [1][4], so the size of any gain varies by skeletal site.
Epistemic
No included primary study randomises anabolic-first against antiresorptive-first; [4] has no reverse-sequence arm and [6] is combination not sequential.
Inferential
The sole superiority test [1] propensity-weights non-concurrent cohorts (months 0-24 vs 12-36), so residual confounding is possible despite E-value adjustment.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct evidence that the anabolic/dual-first sequence gives superior BMD gains versus antiresorptive-only at all three skeletal sites.
“After PSW, over 24 months, compared with DMAb/DMAb, treatment with Romo/DMAb produced significantly greater BMD increases at the lumbar spine [LS], TH, and FN (mean differences: 9.3%, 4.4%, and 4.1%, respectively; all p<0.001).”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women aged ≥55 with TH or FN T-score -2.5 to -3.5, romosozumab-then-denosumab vs denosumab only over 24 months.Key limitations: observational cross-trial comparison · residual confounding possible · no specific N in abstract
Shows the anabolic-first (teriparatide) BMD gain is maintained by antiresorptive consolidation and lost without it, supporting the sequential-therapy limb.
“Patients receiving raloxifene in year 2 had no further change in spine BMD from year 1 (change from baseline, 7.9%), whereas patients receiving no active treatment had a BMD decrease of 2.5% in year 2 (change from baseline, +3.8%).”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women with severe osteoporosis and recent fragility fracture, follow-up treatment after 1 year teriparatide.Key limitations: no antiresorptive-first comparator · open-label · BMD not sequence-superiority endpoint
Supports that adding an antiresorptive to an anabolic agent raises BMD beyond anabolic monotherapy; relevant to the anabolic-based strategy though combination rather than strictly sequential.
“The increase in lumbar spine BMD was 5% ± 6.3% in the ALN and 6% ± 5.2% in the RAL combination groups compared with 2.8% ± 9.3% in the TPTD monotherapy group (p = 0.085 and p = 0.033, respectively).”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women with severe osteoporosis on teriparatide, adding an antiresorptive.Key limitations: combination not sequence design · open-label · clinical relevance of BMD increase stated unknown
Indirect support: the dual-action/anabolic agent gives superior BMD gains, though in a post-bisphosphonate (antiresorptive-first) setting rather than anabolic-first.
“After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups.”
Panel auditInternal validity: low · scope of inference: Postmenopausal women (mean age 73.8) with inadequate response to prior bisphosphonate, switched to a second agent.Key limitations: all arms antiresorptive-first · retrospective · small groups · short follow-up
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent-direction primary evidence led by one robust direct comparison [1] supports superiority, but the thin, post hoc nature of that direct test caps confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised sequence trial. Superiority rests on a single observational comparison [1]; no included primary study randomly assigns anabolic-first versus antiresorptive-first. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial assigning high-risk patients to anabolic-first-then-antiresorptive versus antiresorptive-first-then-anabolic, with BMD at spine, total hip and femoral neck as primary endpoints.
Open question: Does anabolic-first sequencing produce greater BMD gains than antiresorptive-first when patients are randomised to the two orders? Why it is still open: The only direct comparison in the corpus [1] is a post hoc propensity-weighted analysis of non-concurrent cohorts, and no included primary study randomises the sequences.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19